Sanket Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 11-07-2024
- Paid Up Capital ₹ 1.53 M
as on 11-07-2024
- Company Age 41 Year, 21 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 6.90 M
as on 11-07-2024
- Revenue -32.70%
(FY 2021)
- Profit -26.47%
(FY 2021)
- Ebitda -81.17%
(FY 2021)
- Net Worth 4.18%
(FY 2021)
- Total Assets 0.67%
(FY 2021)
About Sanket Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 1.53 M.
The company currently has active open charges totaling ₹6.90 M.
Palak Jain, Arti Jain, Rakesh Jain, and One other member serve as directors at the Company.
- CIN/LLPIN
U24239MH1983PTC031464
- Company No.
031464
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Dec 1983
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Sanket Pharmaceuticals Pvt Ltd offer?
Sanket Pharmaceuticals Pvt Ltd offers a wide range of products and services, including Anti Infective Drugs & Medicines, Malaria Medicine.
Who are the key members and board of directors at Sanket Pharmaceuticals?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Palak Jain  | Director | 01-Oct-2021 | Current |
| Arti Jain | Director | 05-Feb-2021 | Current |
| Rakesh Jain | Director | 26-Feb-2013 | Current |
| Dinesh Jain | Director | 18-Dec-1995 | Current |
Financial Performance of Sanket Pharmaceuticals.
Sanket Pharmaceuticals Pvt Ltd, for the financial year ended 2021, experienced significant reduction in revenue, with a 32.7% decrease. The company also saw a substantial fall in profitability, with a 26.47% decrease in profit. The company's net worth moved up by a moderate rise of 4.18%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sanket Pharmaceuticals?
In 2021, Sanket Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sarvesh Traders Private LtdActive 30 years 10 monthsPalak Jain, Arti Jain and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Corporation Bank Creation Date: 30 Mar 2001 | ₹5.00 M | Open |
Sttae Bank Of India Creation Date: 30 Mar 1995 | ₹0.30 M | Open |
Sttae Bank Of India Creation Date: 12 Jan 1988 | ₹1.60 M | Open |
How Many Employees Work at Sanket Pharmaceuticals?
Unlock and access historical data on people associated with Sanket Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sanket Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sanket Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
